Case Studies
Dermatology
Atopic Dermatitis
Atopic Dermatitis is the most prevalent type of eczema. The drug we developed to treat the inflammation and itch associated with the disease is currently being tested in human clinical trials.
GASTROENTEROLOGY
Ulcerative Colitis (UC)
UC is a chronic disease with no cure. Our work focuses on discovering safer and more effective small-molecule treatments, and we have identified and validated a novel AI-generated target with no previous link to UC.
ONCOLOGY
Glioblastoma Multiforme (GBM)
GBM is a complex, aggressive and lethal brain tumour. Our work focuses on mechanisms that may contribute to the progression and relapse of the disease, and we advanced one of the most promising candidates through to lead optimisation.
NEURODEGENERATIVE DISORDERS
Amyotrophic Lateral Sclerosis
ALS is a progressive and ultimately fatal neurodegenerative disease. Our two programmes aim to identify targets to treat ALS, and we have progressed two targets to candidate seeking and lead optimization.
Drug development licensing partnerships
Our pipeline demonstrates the utility of the Benevolent Platform™, and we are actively exploring strategic licensing partnerships and late-stage development and commercialisation partnerships to deliver our medicines to patients in need.
